Douglas Dieterich, MD

Hepatitis B and hepatitis C behave nothing alike once treatment succeeds. This episode explains why hepatitis B's genomic integration makes true virologic cure fundamentally more complex than hepatitis C clearance.

Guideline inconsistency and treatment thresholds continue to create gaps in chronic hepatitis B care, particularly in primary care settings. This episode also examines what functional cure means for cancer risk and long-term antiviral safety.

Quantitative hepatitis B surface antigen testing is emerging as a critical tool for identifying which patients may respond best to next-generation therapies. This episode reviews new guideline recommendations and finite-duration therapy conversations.

Unlike hepatitis C, chronic hepatitis B does not always progress through classic fibrosis, making liver cancer possible without significant liver damage. This episode reviews how genomic integration drives that risk and how monitoring should adapt.

Chronic hepatitis B remains highly prevalent yet chronically underdiagnosed in the United States. This episode reviews global and domestic epidemiology, new universal screening guidance, and a health-system model built to close the gap.

Chronic hepatitis B is often framed purely as a viral disease, but immune suppression from surface antigen excess is central to how it behaves. This episode examines why targeting that immune dimension is essential to curing it.

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.